The global respiratory biologics sales are estimated to be worth USD 8154.6 million in 2024. The market is expected to reach USD 42,319.9 million by 2034. It is projected to surge at a CAGR of 17.9% in the forecast period 2024 to 2034.
Globally, respiratory diseases like asthma, COPD, and allergic rhinitis are increasing due to rise in air pollution, smoking, and lifestyle changes, necessitating effective treatments like respiratory biologics. Biotechnology advancements have led to the development of targeted biologics therapies, which focus on specific respiratory disease pathways and offer improved efficacy and safety compared to traditional treatments.
The treatment of respiratory diseases is shifting toward respiratory biologics, offering targeted approaches to control symptoms, reduce exacerbations, and enhance patients' quality of life compared to conventional methods. The rise of personalized medicine in respiratory care is influencing the development of new biologics and diagnostics to cater to individual patient's specific genetic makeup and disease characteristics.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | USD 7,248.6 million |
| Estimated Global Respiratory Biologics Market Size (2024E) | USD 8,154.6 million |
| Projected Respiratory Biologics Market Value (2034F) | USD 42,319.9 million |
| Value-based CAGR (2024 to 2034) | 17.9% |
The global respiratory biologics market recorded a historical CAGR of 29% from 2019 to 2023. Due to rising respiratory disease prevalence and healthcare spending, the market has grown globally, attracting investments from developed and emerging markets.
Market expansion strategies aim to address unmet medical needs in diverse regions. Ongoing research and development efforts involving collaborations between academia, industry, and government have fueled the pipeline of respiratory biologics, exploring new therapeutic targets and mechanisms of action.
A key factor driving the growth of the respiratory biologics market is the increasing incidence of respiratory diseases. Respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and other pulmonary disorders are becoming more commonplace worldwide. This increasing prevalence highlights the pressing need for efficient treatment options. It establishes respiratory biologics as an important and quickly growing area of the pharmaceutical and biotechnology industries.
Biotechnology progress has led to novel biologics, like monoclonal antibodies, which provide more targeted treatments for respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). The market is seeing a shift toward better drug delivery mechanisms, such as sophisticated inhaler devices, to improve patient compliance and treatment outcomes.
Alliances and strategic partnerships between academic institutions and pharmaceutical companies are supporting research and development. These are increasing the development of respiratory biologics. In addition, the aging population and increased incidence of respiratory illnesses worldwide drive the need for these cutting-edge treatments.
The respiratory biologics market is expanding in terms of awareness, education, and accessibility as governments concentrate on healthcare policies and initiatives. These factors are contributing to its overall growth and evolution.
Raising awareness and comprehension of the molecular mechanisms underlying respiratory diseases opens up new opportunities for innovative biologics therapies. The rise of precision medicine, which emphasizes tailored therapeutic approaches, fits in well with respiratory biologics' targeted nature and opens up new development opportunities.
The growing elderly population which is more susceptible to respiratory ailments, drives market growth. Government programmes and policies that support healthcare improve accessibility would also push demand. Research & development, partnerships, and collaborations increase market potential and drive the introduction of new treatments.
Mid-sized companies need help in areas like experience, biologics manufacturing infrastructure, and capital, heightening the challenge. Nevertheless, these mid-sized players possess a distinctive advantage in their capacity for focused efforts, particularly within niche therapeutic areas and cutting-edge technologies.
The high cost of biologics therapies for respiratory diseases is set to restrict access for some patients, especially those without adequate insurance coverage or reimbursement programs. Respiratory biologics are limited by insurance coverage, formulary restrictions, and reimbursement policies, with payers imposing strict eligibility criteria for patients with severe disease or treatment failure.
The table below shows the estimated growth rates of the five leading countries. China, France, and the United States are set to record high CAGRs of 18.9%, 16.3%, and 13.7%, respectively, through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 13.7% |
| China | 18.9% |
| Japan | 10.1% |
| Germany | 13.7% |
| France | 16.3% |
The United States is expected to exhibit a CAGR of 13.7% throughout the forecast period. Patient and healthcare provider awareness about the benefits of respiratory biologics therapy is growing. It is taking place through education initiatives, advocacy groups, and disease awareness campaigns, which is set to significantly boost market growth and treatment adherence.
The United States is home to several cutting-edge biotechnology and pharmaceutical enterprises. These companies make significant investments in research and development, which results in identifying and releasing innovative respiratory biologics.
China is expected to grow at a CAGR of 18.9% by 2034. China is becoming a key force in the respiratory biologics market because of its rapidly developing healthcare infrastructure and rising awareness of respiratory disorders.
The demand for cutting-edge treatments is increasing due to the rising prevalence of diseases, including COPD and asthma. The market is also growing because of the government's efforts to improve healthcare access and concentrate on developing biotechnology.
China presents a sizable market for respiratory biologics due to its aging population and growing healthcare awareness. Both local and foreign companies are drawn to the area to take advantage of this potential.
Germany is expected to surge at a CAGR of 13.7% during the forecast period. Germany's strong healthcare system, huge research resources, and focus on innovative treatments are driving the country's respiratory biologics industry.
With Germany's dedication to innovation and first-rate healthcare, the nation is well-positioned to advance respiratory biologics. Germany creates an atmosphere favorable to developing and using innovative biological medicines for respiratory disorders, propelling growth in this rapidly expanding healthcare industry.
Japan is expected to surge at a CAGR of 10.1% by 2034. Japan faces a growing burden of respiratory conditions like asthma, COPD, and allergic rhinitis, necessitating the need for effective treatment options, including respiratory biologics.
Respiratory biologics in Japan offer targeted treatment options for severe or difficult-to-treat respiratory conditions, providing better symptom control and reducing exacerbations compared to traditional medications. Japan's respiratory biologics market is growing due to efforts to improve patient access and affordability, including patient assistance programs and negotiated pricing agreements.
France is projected to rise at 16.3% CAGR during the forecast period. The biotechnology sector in France is fostering innovation in respiratory biologics through research and development, resulting in novel molecules, improved delivery devices, and advanced diagnostic tools for personalized patient treatment.
The government is a key regulatory body responsible for overseeing respiratory biologics therapies' approval and post-market surveillance, significantly influencing their development timelines and commercialization strategies in France. France's respiratory biologics market faces fierce competition from pharmaceutical companies, influenced by factors like pricing strategies, market share, and product differentiation.
The section below shows the intravenous segment dominating by route of administration. It is set to hold a market share of 67.0% in 2024. Based on sales channels, the hospital segment is anticipated to generate a dominant share through 2024. It is likely to generate a share of 44.0% in 2024.
| Segment | Market Share (2024) |
|---|---|
| Intravenous (Route of Administration) | 67.0% |
| Hospital (Sales Channel) | 44.0% |
Respiratory biologics are in high demand because of the growing prevalence of asthma and its profound impact on patients' lives. These cutting-edge therapies effectively relieve asthma by addressing its underlying causes.
Respiratory biologics provide accurate solutions in response to the growing emphasis on individualized therapy, fueling the market's expansion. Owing to their special capacity to target particular pathways, biologics play a pivotal role in respiratory treatment, particularly given the intricate nature of managing asthma.
With their robust infrastructure and resources, hospitals are adept at delivering comprehensive respiratory care services. This includes the diagnosis, treatment, and management of respiratory conditions.
Specialized respiratory care units, dedicated pulmonary function testing labs, and teams of pulmonologists, respiratory therapists, and other healthcare professionals operate within these facilities. Their collective expertise is pivotal in effectively managing respiratory diseases, positioning hospitals as key contributors to the respiratory biologics market.
Respiratory biologics companies are investing heavily in respiratory biologics research & development to advance scientific understanding, expand treatment options, and gain market competitiveness.
For instance
Table 01: Global Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 03: Global Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 04: Global Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 05: Global Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Region
Table 06: North America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 07: North America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 08: North America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 09: North America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 10: Latin America Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 11: Latin America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 12: Latin America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 13: Latin America Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 14: East Asia Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 15: East Asia Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 16: East Asia Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 17: East Asia Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 18: South Asia & Pacific Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 19: South Asia & Pacific Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 20: South Asia & Pacific Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 21: South Asia & Pacific Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 22: Western Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 23: Western Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 24: Western Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 25: Western Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 26: Eastern Europe Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 27: Eastern Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 28: Eastern Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 29: Eastern Europe Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Table 30: Middle East and Africa Market Value (US$ million) Analysis 2019 to 2023 and Forecast 2024 to 2034, by Country
Table 31: Middle East and Africa Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Disease Indication
Table 32: Middle East and Africa Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Route of Administration
Table 33: Middle East and Africa Market Value (US$ million) Analysis and Forecast 2019 to 2034, by Sales Channel
Figure 1: Global Market Value (US$ million) Analysis, 2019 to 2023
Figure 2: Global Market Forecast & Y-o-Y Growth, 2024 to 2034
Figure 3: Global Market Absolute $ Opportunity (US$ million) Analysis, 2023 to 2034
Figure 4: Global Market Value Share (%) Analysis 2024 to 2034, by Disease Indication
Figure 5: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Disease Indication
Figure 6: Global Market Attractiveness Analysis 2024 to 2034, by Disease Indication
Figure 7: Global Market Value Share (%) Analysis 2024 to 2034, by Route of Administration
Figure 8: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Route of Administration
Figure 9: Global Market Attractiveness Analysis 2024 to 2034, by Route of Administration
Figure 10: Global Market Value Share (%) Analysis 2024 to 2034, by Sales Channel
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Sales Channel
Figure 12: Global Market Attractiveness Analysis 2024 to 2034, by Sales Channel
Figure 13: Global Market Value Share (%) Analysis 2024 to 2034, by Region
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Region
Figure 15: Global Market Attractiveness Analysis 2024 to 2034, by Region
Figure 16: North America Market Value (US$ million) Analysis, 2019 to 2023
Figure 17: North America Market Value (US$ million) Forecast, 2024 to 2034
Figure 18: North America Market Value Share, by Disease Indication (2024 E)
Figure 19: North America Market Value Share, by Route of Administration (2024 E)
Figure 20: North America Market Value Share, by Sales Channel (2024 E)
Figure 21: North America Market Value Share, by Country (2024 E)
Figure 22: North America Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 24: North America Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 25: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 26: United States Market Value Proportion Analysis, 2023
Figure 27: Global Vs. United States Growth Comparison, 2024 to 2034
Figure 28: United States Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 29: United States Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 30: United States Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 31: Canada Market Value Proportion Analysis, 2023
Figure 32: Global Vs. Canada. Growth Comparison, 2024 to 2034
Figure 33: Canada Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 34: Canada Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 35: Canada Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 36: Mexico Market Value Proportion Analysis, 2023
Figure 37: Global Vs. Mexico Growth Comparison, 2024 to 2034
Figure 38: Mexico Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 39: Mexico Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 40: Mexico Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 41: Latin America Market Value (US$ million) Analysis, 2019 to 2023
Figure 42: Latin America Market Value (US$ million) Forecast, 2024 to 2034
Figure 43: Latin America Market Value Share, by Disease Indication (2024 E)
Figure 44: Latin America Market Value Share, by Route of Administration (2024 E)
Figure 45: Latin America Market Value Share, by Sales Channel (2024 E)
Figure 46: Latin America Market Value Share, by Country (2024 E)
Figure 47: Latin America Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 49: Latin America Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 50: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 51: Brazil Market Value Proportion Analysis, 2023
Figure 52: Global Vs. Brazil. Growth Comparison, 2024 to 2034
Figure 53: Brazil Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 54: Brazil Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 55: Brazil Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 56: Chile Market Value Proportion Analysis, 2023
Figure 57: Global Vs. Chile Growth Comparison, 2024 to 2034
Figure 58: Chile Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 59: Chile Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 60: Chile Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 61: East Asia Market Value (US$ million) Analysis, 2019 to 2023
Figure 62: East Asia Market Value (US$ million) Forecast, 2024 to 2034
Figure 63: East Asia Market Value Share, by Disease Indication (2024 E)
Figure 64: East Asia Market Value Share, by Route of Administration (2024 E)
Figure 65: East Asia Market Value Share, by Sales Channel (2024 E)
Figure 66: East Asia Market Value Share, by Country (2024 E)
Figure 67: East Asia Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 68: East Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 69: East Asia Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 70: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 71: China Market Value Proportion Analysis, 2023
Figure 72: Global Vs. China Growth Comparison, 2024 to 2034
Figure 73: China Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 74: China Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 75: China Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 76: Japan Market Value Proportion Analysis, 2023
Figure 77: Global Vs. Japan Growth Comparison, 2024 to 2034
Figure 78: Japan Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 79: Japan Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 80: Japan Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 81: South Korea Market Value Proportion Analysis, 2023
Figure 82: Global Vs South Korea Growth Comparison, 2024 to 2034
Figure 83: South Korea Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 84: South Korea Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 85: South Korea Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 86: South Asia & Pacific Market Value (US$ million) Analysis, 2019 to 2023
Figure 87: South Asia & Pacific Market Value (US$ million) Forecast, 2024 to 2034
Figure 88: South Asia & Pacific Market Value Share, by Disease Indication (2024 E)
Figure 89: South Asia & Pacific Market Value Share, by Route of Administration (2024E)
Figure 90: South Asia & Pacific Market Value Share, by Sales Channel (2024 E)
Figure 91: South Asia & Pacific Market Value Share, by Country (2024 E)
Figure 92: South Asia & Pacific Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 93: South Asia & Pacific Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 94: South Asia & Pacific Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 95: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 96: India Market Value Proportion Analysis, 2023
Figure 97: Global Vs. India Growth Comparison, 2024 to 2034
Figure 98: India Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 99: India Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 100: India Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 101: ASEAN Countries Market Value Proportion Analysis, 2023
Figure 102: Global Vs. ASEAN Countries Growth Comparison, 2024 to 2034
Figure 103: ASEAN Countries Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 104: ASEAN Countries Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 105: ASEAN Countries Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 106: Australia & New Zealand Market Value Proportion Analysis, 2024
Figure 107: Global Vs. Australia & New Zealand Growth Comparison, 2024 to 2034
Figure 108: Australia & New Zealand Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 109: Australia & New Zealand Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 110: Australia & New Zealand Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 111: Western Europe Market Value (US$ million) Analysis, 2019 to 2023
Figure 112: Western Europe Market Value (US$ million) Forecast, 2024 to 2034
Figure 113: Western Europe Market Value Share, by Disease Indication (2024 E)
Figure 114: Western Europe Market Value Share, by Route of Administration (2024 E)
Figure 115: Western Europe Market Value Share, by Sales Channel (2024 E)
Figure 116: Western Europe Market Value Share, by Country (2024 E)
Figure 117: Western Europe Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 118: Western Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 119: Western Europe Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 120: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: United Kingdom Market Value Proportion Analysis, 2023
Figure 122: Global Vs. United Kingdom Growth Comparison, 2024 to 2034
Figure 123: United Kingdom Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 124: United Kingdom Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 125: United Kingdom Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 126: Germany Market Value Proportion Analysis, 2023
Figure 127: Global Vs. Germany Growth Comparison, 2024 to 2034
Figure 128: Germany Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 129: Germany Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 130: Germany Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 131: Italy Market Value Proportion Analysis, 2023
Figure 132: Global Vs. Italy Growth Comparison, 2024 to 2034
Figure 133: Italy Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 134: Italy Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 135: Italy Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 136: France Market Value Proportion Analysis, 2023
Figure 137: Global Vs France Growth Comparison, 2024 to 2034
Figure 138: France Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 139: France Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 140: France Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 141: Spain Market Value Proportion Analysis, 2023
Figure 142: Global Vs Spain Growth Comparison, 2024 to 2034
Figure 143: Spain Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 144: Spain Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 145: Spain Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 146: Nordic Countries Market Value Proportion Analysis, 2023
Figure 147: Global Vs Nordic Countries Growth Comparison, 2024 to 2034
Figure 148: Nordic Countries Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 149: Nordic Countries Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 150: Nordic Countries Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 151: BENELUX Market Value Proportion Analysis, 2023
Figure 152: Global Vs BENELUX Growth Comparison, 2024 to 2034
Figure 153: BENELUX Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 154: BENELUX Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 155: BENELUX Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 156: Eastern Europe Market Value (US$ million) Analysis, 2019 to 2023
Figure 157: Eastern Europe Market Value (US$ million) Forecast, 2024 to 2034
Figure 158: Eastern Europe Market Value Share, by Disease Indication (2024 E)
Figure 159: Eastern Europe Market Value Share, by Route of Administration (2024 E)
Figure 160: Eastern Europe Market Value Share, by Sales Channel (2024 E)
Figure 161: Eastern Europe Market Value Share, by Country (2024 E)
Figure 162: Eastern Europe Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 163: Eastern Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 164: Eastern Europe Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 165: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 166: Russia Market Value Proportion Analysis, 2023
Figure 167: Global Vs. Russia Growth Comparison, 2024 to 2034
Figure 168: Russia Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 169: Russia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 170: Russia Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 171: Hungary Market Value Proportion Analysis, 2023
Figure 172: Global Vs Hungary Growth Comparison, 2024 to 2034
Figure 173: Hungary Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 174: Hungary Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 175: Hungary Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 176: Poland Market Value Proportion Analysis, 2024
Figure 177: Global Vs Poland Growth Comparison, 2024 to 2034
Figure 178: Poland Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 179: Poland Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 180: Poland Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 181: Middle East and Africa Market Value (US$ million) Analysis, 2019 to 2023
Figure 182: Middle East and Africa Market Value (US$ million) Forecast, 2024 to 2034
Figure 183: Middle East and Africa Market Value Share, by Disease Indication (2024 E)
Figure 184: Middle East and Africa Market Value Share, by Route of Administration (2024E)
Figure 185: Middle East and Africa Market Value Share, by Sales Channel (2024 E)
Figure 186: Middle East and Africa Market Value Share, by Country (2024 E)
Figure 187: Middle East and Africa Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 188: Middle East and Africa Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 189: Middle East and Africa Market Attractiveness Analysis by Sales Channel, 2024 to 2034
Figure 190: Middle East and Africa Market Attractiveness Analysis by Country, 2024 to 2034
Figure 191: Saudi Arabia Market Value Proportion Analysis, 2023
Figure 192: Global Vs Saudi Arabia Growth Comparison, 2024 to 2034
Figure 193: Saudi Arabia Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 194: Saudi Arabia Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 195: Saudi Arabia Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 196: Türkiye Market Value Proportion Analysis, 2023
Figure 197: Global Vs. Türkiye Growth Comparison, 2024 to 2034
Figure 198: Türkiye Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 199: Türkiye Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 200: Türkiye Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 201: South Africa Market Value Proportion Analysis, 2023
Figure 202: Global Vs. South Africa Growth Comparison, 2024 to 2034
Figure 203: South Africa Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 204: South Africa Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 205: South Africa Market Share Analysis (%) by Sales Channel, 2024 to 2034
Figure 206: Other African Union Market Value Proportion Analysis, 2023
Figure 207: Global Vs Other African Union Growth Comparison, 2024 to 2034
Figure 208: Other African Union Market Share Analysis (%) by Disease Indication, 2024 to 2034
Figure 209: Other African Union Market Share Analysis (%) by Route of Administration, 2024 to 2034
Figure 210: Other African Union Market Share Analysis (%) by Sales Channel, 2024 to 2034
The market was valued at USD 7,248.6 million in 2023.
The market is set to reach USD 42,319.9 million by 2034.
The asthma segment by disease indication is set to hold an 82.3% share in 2024.
Demand for the market increased at a 29% CAGR from 2019 to 2023.
The market is expected to reach USD 8,154.6 million.
Explore Similar Insights
Respiratory Biologics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
